The biomedical landscape of the United States is facing a quiet but significant crisis: the systematic dismantling of expert advisory committees within key federal health agencies. A new report reveals that Robert F. Kennedy Jr., during his time as head of the Commission to Combat COVID-19, initiated a wave of terminations and undermined the work of numerous panels responsible for guiding policy on everything from vaccine development to Alzheimer’s disease research. More than a quarter of these committees have been affected, raising concerns about the future of evidence-based public health decision-making.
The impact extends across the Department of Health and Human Services (HHS), with nine advisory committees at the Centers for Disease Control and Prevention (CDC) terminated, and four at the Food and Drug Administration (FDA) dissolved. This isn’t simply a matter of bureaucratic streamlining; the committees targeted represent a broad spectrum of critical health areas, including childhood vaccines, heritable diseases, Alzheimer’s, health equity, and even long COVID. The erosion of these expert voices, critics say, threatens to politicize public health and stifle scientific progress. Understanding the implications of these changes requires a closer look at the role these committees play and the concerns surrounding their abrupt disruption.
Among the terminated advisory bodies was the National Institutes of Health (NIH) Center for Scientific Review Advisory Council, established in 1988. This council didn’t directly review grant applications, but instead advised NIH leaders on how to strategically allocate research funding. The dismantling of such a foundational group signals a broader shift in how the government approaches scientific investment. The CDC’s Advisory Committee on Immunization Practices (ACIP), responsible for developing vaccine recommendations, was also among those undermined, according to the report. ACIP holds three regular meetings each year to review data and formulate guidance on vaccine use in the U.S.
Undermining Trust in Public Health
The report highlights a particularly troubling development within the Interagency Autism Coordinating Committee (IACC). In January, HHS appointed 21 new members to this panel, which monitors autism research and progress on causes, prevention, diagnosis, and treatment. At least eight of these appointees reportedly subscribe to the debunked claim that vaccines cause autism – a belief actively promoted by Kennedy. This prompted autism researchers and advocates to form a competing, non-governmental advisory committee to counter what they anticipate will be misinformation emanating from the federal panel. This parallel effort underscores the deep distrust that has emerged and the perceived require for an independent source of scientific guidance.
At the FDA, the terminated advisory committees specialized in areas like arthritis, medical imaging drugs, pharmaceutical sciences, and patient engagement. These groups provided crucial external expertise to the agency during the drug approval process and in evaluating the safety and efficacy of medical devices. Their absence could lead to delays in bringing new treatments to market or, more concerningly, to the approval of products that haven’t undergone rigorous scrutiny. The loss of these committees isn’t merely procedural; it’s a direct challenge to the FDA’s long-standing commitment to scientific rigor.
Impact on Key Health Areas
The scope of the affected committees is remarkably broad. Beyond those already mentioned, panels focused on healthcare infection control, rural health, novel and exceptional technology, and the US Preventive Services Task Force (USPSTF) – which provides recommendations on preventative health screenings – were also targeted. The USPSTF’s recommendations, for example, are widely used by healthcare providers to guide preventative care for millions of Americans. Any disruption to this process could have far-reaching consequences for public health outcomes.
Michael Abrams, a senior health researcher at Public Citizen and author of the report, expressed strong condemnation of the actions. “All Americans, including patients, lawmakers, and scientists, have every right to be incensed at the damage Trump has done to federal health advisory committees,” Abrams stated. “Trump’s actions are undermining biomedical research, long-standing processes for the approval of new drugs and medical devices, and federal vaccine policy. Silencing and biasing external experts makes HHS vulnerable to stagnation and corruption that erodes the health of all Americans.”
The report emphasizes that the damage inflicted on these advisory committees may be difficult to quickly reverse. Rebuilding trust in these panels and attracting qualified experts will require a concerted effort to restore scientific integrity and transparency within the HHS. The long-term consequences of this disruption remain to be seen, but the initial assessment paints a concerning picture for the future of public health in the United States.
The situation raises fundamental questions about the role of scientific expertise in policymaking and the potential for political interference to undermine public health. As the HHS navigates these challenges, the need for independent, evidence-based guidance has never been greater. The next scheduled meeting of the ACIP is currently slated for February 26, 2026, according to the CDC website, and will be a key indicator of whether the committee can effectively function in its diminished capacity.
What are your thoughts on the impact of these committee terminations? Share your comments below, and please share this article with your network to raise awareness about this critical issue.
